NEW YORK – Qlucore said Monday that it will integrate its flagship Omics Explorer software with Clarivate's MetaCore bioinformatics analysis platform for pathway analysis, enabling researchers to interpret and dig down into multiomics data more easily.
Lund, Sweden-based Qlucore's Omics Explorer provides fast, simple, visual analysis of measured data from a wide range of sources and instruments. MetaCore offers manually curated content for drug development, including validated pathway data to identify and analyze novel biomarkers, targets, and mechanisms of action.
Publicly traded, London-based Clarivate is an analytics firm formed in 2016 after Thomson Reuters sold its intellectual property and science business to two private equity firms.
"The combination of Qlucore Omics Explorer and MetaCore will make it easier and faster for research scientists to obtain clear and validated results," Qlucore President Carl-Johan Ivarsson said in a statement.
"Partnering with Qlucore will enhance the experience of researchers and aid the acceleration of scientific innovation," added Gavin Coney, VP for channels and alliances in the science group at Clarivate.